Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey - Scorecard - MDSpire

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey

  • By

  • Tyler A. Lanman

  • L. Nicolas Gonzalez Castro

  • Haley K. Perlow

  • Gilbert Youssef

  • Roy E. Strowd

  • Michael T. Milano

  • Marina Kushnirsky

  • Ankush Bhatia

  • Patrick Y. Wen

  • Julie J. Miller

  • Benjamin J. Rich

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Current Approaches to Managing IDH-Mutant Gliomas: Insights from a Multidisciplinary, Multi-Institutional Survey

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingSpecify types of multidisciplinary settings involved.

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider a combination of surgery, radiotherapy, and chemotherapy based on individual patient scenarios.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clarify the context for considering Vorasiidenib.

        Clinical Best Practices

        • remove

        Related Resources & Content

        Original Source(s)

        Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey

        • by Tyler A. Lanman, L. Nicolas Gonzalez Castro, Haley K. Perlow, Gilbert Youssef, Roy E. Strowd, Michael T. Milano, Marina Kushnirsky, Ankush Bhatia, Patrick Y. Wen, Julie J. Miller, Benjamin J. Rich

        • June 8, 2026

        Related Content

        A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer

        Endocrine-driven inflammatory–epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis

        Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy